Last updated: July 6, 2026
What is ACTHAR GEL (autoinjector) and what drives demand?
ACTHAR Gel (repository corticotropin injection) is marketed for selected inflammatory and immunologic conditions, with commercial focus on dermatologist/neurologist and hospital specialty channels depending on indication mix. The core demand drivers are (1) payer coverage and prior authorization outcomes, (2) clinical inertia versus competing steroid regimens, (3) availability and administration convenience for inpatient and outpatient settings, and (4) manufacturer supply continuity for a product that has historically experienced intermittent supply pressure.
Commercial product format impact. The “autoinjector” presentation is intended to reduce administration friction versus manual reconstitution/needle technique for caregivers and facilities. Demand behavior is typically more sensitive to reimbursement and availability than to pure convenience, but autoinjector packaging can improve treatment persistence for ongoing regimens and reduce workflow cost, which can matter in specialty infusion and clinic models.
Category economics. Repository corticotropin sits in a crowded anti-inflammatory landscape. Its pricing power depends on the extent to which payers accept ACTHAR as a cost-effective alternative to high-dose corticosteroids or other immunomodulators, and on the availability of lower-cost therapeutic substitutes under formulary rules.
How has ACTHAR Gel (autoinjector) performed financially and what is the sales trajectory?
A complete financial trajectory requires current-year revenue and quarter-by-quarter sales data, typically sourced from company reporting and financial databases. That information is not provided in the prompt, and producing an accurate trajectory without it would risk incorrect figures.
No sales chart, revenue range, or time-series can be stated here without verifiable numeric inputs.
When does ACTHAR Gel lose exclusivity and what do patent timelines imply for future revenue?
A reliable exclusivity and patent-loss view depends on the Orange Book status for each approved ACTHAR presentation, plus the patent term schedule for method-of-use and formulation protections and any applicable patent term extensions. The prompt does not include Orange Book listings, patent numbers, or expiration dates.
No exclusivity calendar can be produced accurately without those identifiers.
What patents protect ACTHAR Gel (autoinjector) and how strong is the patent estate?
Patent strength analysis requires (1) the Orange Book patent list tied to the autoinjector NDA/BLA entry, (2) prosecution histories or assignment data for key patents, and (3) litigation or PTAB outcomes affecting enforceability. None of that information is included.
A defensible “how many patents” answer and enforceability view cannot be completed from the provided input.
What is the Orange Book status of ACTHAR Gel (autoinjector)?
Orange Book status is citation- and entry-specific: it requires the NDA number for the autoinjector, the listed dosage form (gel), route, and the patents covering each listed product. The prompt contains no NDA identifier or Orange Book listing.
No Orange Book table can be built without the underlying listing.
What generic entry risks exist for ACTHAR Gel (autoinjector), including Paragraph IV?
Generic entry risk depends on whether the product is eligible for an ANDA pathway (and whether the agency recognizes it as a new drug product with replicability constraints) and on whether any ANDA with an IV certification has been filed. The prompt provides no ANDA filings, no Paragraph IV notices, and no court dockets.
A correct risk assessment needs those concrete filings and the associated litigation outcomes.
How does ACTHAR Gel (autoinjector) compare with competing repository corticotropin and steroid/biologic alternatives?
A comparison that supports market share and price realism requires (1) competitor list by indication, (2) relative efficacy and safety positioning accepted by clinicians and payers, and (3) observed payer formulary tiering and step therapy requirements. The prompt does not include competitive set or payer decision framework.
No rigorous competitor comparison can be completed without product-level and indication-level data.
What patent litigation affects ACTHAR Gel and what settlement history matters?
Patent litigation and settlements are docket- and case-specific (case caption, court, filing dates, asserted patents, and settlement terms affecting launch dates). The prompt provides no litigation timeline, parties, or asserted patents.
A litigation-driven market forecast cannot be grounded without docket-level facts.
What is the FDA regulatory status and what does it mean for launch timing?
Regulatory status needs FDA review milestones (approval dates, supplement history for the autoinjector), labeling changes, and any post-marketing actions that affect supply or indications. The prompt includes no NDA details, approval dates, or supplement history.
No actionable regulatory timing can be produced without those identifiers.
How do reimbursement and channel dynamics shape ACTHAR Gel (autoinjector) revenue?
Channel and reimbursement dynamics are measurable through payer coverage policies, claim denial/approval rates, specialty pharmacy versus buy-and-bill mix, and hospital contract structures. The prompt contains no reimbursement dataset, no payer list, and no distribution mix metrics.
No quantifiable reimbursement analysis can be made.
Key takeaways
- ACTHAR Gel (autoinjector) demand is driven primarily by reimbursement and administration practicality, but revenue trajectory depends on supply continuity, payer coverage behavior, and persistence in chronic or relapsing indications.
- A defensible exclusivity, Orange Book, patent strength, and generic entry risk assessment requires Orange Book listing identifiers, patent numbers, expiration dates, and any ANDA Paragraph IV and litigation dockets.
- The prompt does not include the sales figures, Orange Book entry details, or patent/litigation data needed to produce an accurate financial trajectory and patent-exclusivity calendar.
FAQs
- What NDA label and dosage-form identifiers define ACTHAR Gel autoinjector for Orange Book matching?
- How do payer step-therapy and prior-authorization policies typically affect repository corticotropin utilization versus high-dose corticosteroids?
- What supply constraints and manufacturing incidents have historically affected ACTHAR Gel availability and sales volatility?
- Which patent categories (method-of-use, formulation, manufacturing/process) usually control repository corticotropin durability, and how do they map to FDA supplements?
- What are the typical triggers for ANDA or biosimilar-style competitive pressure in older specialty injectables like ACTHAR, and what market signals precede launch?
References
- APA style citations would be listed here only after specific source inputs are provided.
-patent-expirations.png "ACTHAR GEL (AUTOINJECTOR) drug patent expirations")
